Healthcare · Biotechnology · NASDAQ

Summit Therapeutics PLC (SMMT) Stock Price, Analysis & Trade Signals

$9.95-0.62 (-5.87%)

Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738,…

SMMT key stats

Market Cap
$7.96B
P/E Ratio
0
Forward P/E
3.72
EPS
-1.06
52 Week Range
$9.88 – $29.23
50-Day Avg
15.74
200-Day Avg
16.06
Revenue Growth (Qtr YoY)
-100%
Profit Margin
0%
Operating Margin (TTM)
0%
Beta
-1.52
Volume
7.22M
30-Day Avg Volume
6.5M
Next Earnings
Feb 22, 2027
Estimated EPS
-0.34
CEO
Robert W. Duggan
Employees
265
IPO Date
Mar 5, 2015

SMMT on X: what traders are saying

  • Michael Taylor @Mike_Taylor1972 · Nov 15, 2026

    $SMMT A long shot PDUFA for (IMHO) an active drug developed (in the case of the FDA submission) in a high-risk trial structure. No OS in 1’ endpoint. FDA only accepting OS is known. Next we get a look at Harmoni3, a better designed study to demonstrate OS. Ivonescimab IMHO hits…

SMMT analyst rating & price target

17 analysts rate SMMT Buy on consensus.

1Strong Buy
10Buy
6Hold
0Sell
0Strong Sell

Consensus price target: $29.77 (+199.2% upside from $9.95)

Recent SMMT insider transactions

InsiderDateTransactionSharesValue
DUGGAN ROBERT W
director, 10 percent owner, Co-Chief Executive Officer
Jun 12, 2026Purchase3,810,000$49.99M
Zanganeh Mahkam
director, 10 percent owner, Co-Chief Executive Officer
Jun 12, 2026Purchase3,810,000$49.99M
Soni Manmeet Singh
director, COO and CFO
Jun 4, 2026Purchase25,000$361.5K
Soni Manmeet Singh
director, COO and CFO
Jun 4, 2026Purchase25,000$360.75K
Zanganeh Mahkam
director, 10 percent owner, Co-Chief Executive Officer
Jun 4, 2026Purchase100,000$1.46M

Summit Therapeutics PLC annual revenue & net income

Fiscal yearRevenueRevenue YoYNet income
2025$0—$-1.08B
2024$0—$-176.77M
2023$0-100%$-482.37M

Latest SMMT news

Stock data for SMMT: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics